A novel mRNA cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return, according to ABC News. The outlet described the treatment as a "first-of-its-kind cancer vaccine." The ABC News report carries no listed author.

The New York Times also covered the development in a report by Nina Agrawal. Its headline, Melanoma Vaccine Ushers in New Hope for Cancer Patients, describes the vaccine as bringing new hope to cancer patients. The Times summary adds that, beyond melanoma, scientists are studying cancer vaccines for glioblastoma, pancreatic cancer and more. According to that summary, the research under way is not limited to melanoma.

The two reports differ in emphasis rather than in substance. ABC News centers on the reduced chance of tumor return, while the Times centers on broader hope and the wider field of cancer vaccine research. The ABC News headline names the vaccine as a novel mRNA cancer vaccine, while the Times headline does not use the term mRNA.

Neither summary provides the size of the reduction, the number of patients studied, or the time frame of the research. Neither summary states whether the vaccine has been approved for use, or at what stage the other cancer vaccines under study are. Those points are not covered in the material available for this story.

Both reports concern melanoma patients. The ABC News and Times stories differ in attribution as well, since the ABC News report has no listed author while the Times report is credited to Nina Agrawal.

Sources: ABC News: A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning; The New York Times: Melanoma Vaccine Ushers in New Hope for Cancer Patients.